中文 ENGLISH

About AVATARGET

Company Profile

-- All-inclusive Organ-on-a-chip Solutions Provider

Avatarget Co., Ltd. (Avatarget) is dedicated to R&D and production of organs-on-chips, smart equipments, biological reagents, and other products and services, aiming to build a whole-industry-chain ecosystem for organs-on-chips. It also desires to innovate and break through the limitations of traditional animal models and 2D cell models to address species differences and achieve 3D dynamic cultivation of in vitro models. Also, it seeks to create a highly simulated human body micro-environment and enhance the accuracy of experimental data in order to provide precise and effective products and solutions for users in fields such as tumor precision medicine, disease modeling, drug screening, drug evaluation, cosmetics evaluation, regenerative medicine research and space medicine research.

Big

R&D Lab

Products &
Applications

Percentage of
PhDs

Percentage of R&D personnel

Vision

Become a leader in the field of OoCs

Mission

Linking Organchip, Linking Health

Values

Truth Innovation Endeavor Cooperation mutual benefits

2024

The research project on the mechanism and protection of cardiovascular function changes in weightlessness based on organ chips was selected as one of the "Seven Major Advances in Space Human Research"

2024

Avatarget was selected into the list of "Jiangsu Postdoctoral Innovation and Practice Base"

2024

Avatarget participated in the release of expert consensus on liver organ chips for drug safety prediction

2024

"Multimodal Precision Measurement Technology and Application of Human Organ Chips" won the second prize of this year's Golden Bridge Award

2024

China's first organ chip technical standard "General Technical Requirements for Skin Chips" was officially released

2024

Avatarget was selected into the list of "Potential Unicorn Enterprises in Jiangsu"

2024

The project of human organ-on-chip and multimodal precision measurement method construction selected as one of China’s Top 10 Science Advances in 2023

2024

Recognized as a High-Growth Innovative Enterprise in Suzhou New District in 2023

2023

Recognized as a national high-tech enterprise, and completed the Pre-A+ round of financing led by Tongfang Investment

2023

Included in the List of Potential Unicorn Companies in Jiangsu in 2023; launched Huawei PanGu+OoC, the world’s first medical model in human OoC

2023

Completed the first domestic space OoC culture experiment in Chinese’s space station, also the first international Taikonaut-Blood-Vessels-on-a-Chip study

2023

Cooperated with Hengrui Pharmaceuticals in obtaining the clinical trial approval for China’s first new drug using OoC data

2022

Our OoC project selected for the Exhibition on the Achievements of the New Overseas Chinese in Scientific and Technological Innovation over the Past Decade

2022

Completed the Pre-A round of financing led by Fosun Health Capital

2022

Won the top prize in the 1st National Disruptive Technology Innovation Competition

2021

Jiangsu AVATARGET Biotechnology Co., Ltd. was established

China's first

IND application with organ chips

China's first

Space-borne organ chip

China's first

Organ chip standard

World's first

Biomedical large scale model based on organ chip

Patent Portfolio

Through industry-university-research transformation and independent research and development, Avatarget has deployed more than 120 patents, of which invention patent applications account for 56%. The patent distribution covers core products such as organ chips, biological models and materials, instruments and equipment, and software.

Value Recognition

Since its establishment, AVATARGET has achieved a number of awards and honors. In addition, we have made achievements such as “China’s first OoC to enter the space station for scientific experiments”, “China’s first OoC for IND application”, and “the technical standard for OoCs approved in China”, and completed the Pre-A &A+rounds of financing of nearly RMB200 million led by Fosun Health Capital.

Ava’target (Alpha Target) Strive for Perfection

Our human OoC project has crossed the last kilometer from the R&D to application.

Avatar'get (Avatar Get) Substitution Test

We are building a full industry chain ecosystem of OoC technologies to gain insights into the mysteries of life sciences, contribute to medical technology advancement, and meet the individual needs of patients.

2024-03

2024-01

2023-08

2023-05

2022-12

2022-08

2022-06

2021-01

2020-02

2019-01

2018-01

2013-01

2011-01

2010-01

The project of human organ-on-chip and multimodal precision measurement method construction selected as one of China’s Top 10 Science Advances in 2023

The Center of NMPA issued the Technical Guidelines on Non-clinical Studies of Human Stem Cell-based Products, which explicitly includes new technologies such as organoid into the evaluation models for non-clinical studies of human stem cell-based

The first space OoC culture experiment in Chinese’s space station, also the first international Taikonaut-Blood-Vessels-on-a-Chip study

HRS-1893 tablets were approved for clinical trials, which is the first breakthrough of organoid data outside the realm of CGT drugs

U.S. President Biden signed into law the FDA Modernization Act 2.0, eliminating federal mandatory requirement for animal testing for new and generic drugs

General Technical Requirement of Skin-on-a-chip, China’s first draft technical standard for OoCs, was published

For the first time, the FDA had approved the clinical trial of an investigational therapy based solely on preclinical efficacy data obtained in human OoC studies

The U.S. House of Representatives passed the Food and Drug Amendments of 2022, which includes OoCs and Microphysiological Systems (MPSs) as independent systems for evaluating drugs in non-clinical trials

Organoid research has been approved as a key special project of the National Key R&D Program in China’s 14th Five-Year Plan

The Center of NMPA published the Technical Guidelines on Nonclinical Studies of Genetically Modified Cell Therapy Products, allowing for the use of cell- and tissue-based models to provide useful supplemental information for efficacy and safety evaluation

Southeast University in China developed a bronchial-lung-on-chip that could be used for the evaluation of COVID-19 infections and treatments, and applied it at the Jiangsu Provincial Center for Disease Control and Prevention

FDA used lung-on-chips to evaluate the safety of COVID-19 vaccines and their protective immunity against SARS-CoV-2

The U.S. Environmental Protection Agency (EPA) has announced that it will stop funding all mammal testing by 2035

California has banned cosmetic testing on animals

The EU has imposed a ban from testing finished cosmetic products and cosmetic ingredients on animals and from marketing finished cosmetic products and ingredients which were tested on animals

The U.S. government was the first to announce the launch of a human body-on-a-chip program, aiming to develop human body-on-a-chips for new drug development and toxicity prediction

Harvard University successfully developed the human lung-on-a-chip

Partners

Walk with you, side by side with success, we are here waiting for you to create the future together!

北京协和医院

中源生物

香港大学

301解放军总医院

东南大学

鼓楼医院

恒瑞

华中科技大学

集萃药康

江苏省疾病预防控制中心

江苏省人民医院

江苏省肿瘤医院

凯基生物

南京大学

南京正大天晴

赛赋医药

苏大附一医院

泰格医药

先声药业

昭衍

Honor

第一届江苏省信息消费大赛总决赛产品创新二等奖
中国创新创业大赛江苏赛区优秀企业
中国第一个进入空间站并实施科学实验的器官芯片
中国第一个器官芯片技术标准
中国第一个用于申请新药IND的器官芯片

Service Hotline

0512-65367666

WeChat

Zhihu

Bilibili

Business License

We use optional cookies to improve your experience on our website, including through social media connections, and to personalize ads based on your online activity. If you refuse optional cookies, we will only use cookies that are necessary to provide you with the services.Privacy Statement